CURRICULUM VITAE Hendrik Peter Nicolas Scholl

Transcription

CURRICULUM VITAE
Hendrik Peter Nicolas Scholl
October 1, 2013
DEMOGRAPHIC INFORMATION
Current Title and Appointments
Dr. Frieda Derdeyn Bambas Professor of Ophthalmology
The Wilmer Eye Institute, Johns Hopkins University Medical School
Director, Retinal Degeneration Clinic (Retina Division, Wilmer Eye Institute)
Director, Visual Neurophysiology Service (Johns Hopkins Hospital)
Co-director of the Johns Hopkins Center for STem Cells and Ophthalmic Regenerative Medicine (STORM)
Personal Data
phone:
e-mail:
Wilmer Eye Institute
Johns Hopkins University
748 Maumenee Building
1800 Orleans Street
Baltimore, MD 21287-9277
(443) 287 5495
[email protected]
Education and Training (in chronological order)
Doctoral/graduate
1989 – 1997
Medical Doctor (Dr. med.), Medical Faculty, University of Tübingen, Germany
Thesis: Motion thresholds of colored stimuli of different luminance contrasts are
increased in ocular hypertension and early primary-open-angle-glaucoma
1989 – 1997
Magister Artium (Master of Arts), University of Tübingen (Faculty of Philosophy)
Thesis: Remembrance and authenticity. Husserl‘s, Bergson‘s and Heidegger‘s
philosophy of time with comments on Proust
1/1/1994 – 5/31/1994
Medical School, Brown University, Providence, Rhode Island, USA
Clinical Clerkship: Medicine; Electives: (1) Ophthalmology, (2) Emergency Medicine
Postdoctoral
1997 – 2001
Resident in Ophthalmology and Post-Doc Researcher, University Eye Hospital Tübingen
Training in anterior and posterior segment clinical ophthalmology
Specialized Clinic “Inherited Retinal Dystrophies”
Head of the Lab for Cone-type specific Electroretinography
10/1/2001 – 9/30/2003 Clinical Research Fellowship in Medical Retinal Disease, Moorfields Eye Hospital,
London, UK; Research group Prof. Alan C. Bird
Research Fellowship of the German Research Foundation (DFG)
1/1/2004 – 12/31/2006 Heisenberg-Fellowship of the German Research Foundation (DFG) “Phenotyping,
genotyping and genotype-phenotype correlation in age-related maculopathy (ARM) and
macular degeneration (AMD)”
Professional Experience
10/1/2004 – 2/14/2010 Privatdozent (Associate Professor), Medical Faculty, University of Bonn, Germany
Consultant Ophthalmologist (Oberarzt), Vitreoretinal Surgeon and Research Coordinator
Dept. of Ophthalmology, University of Bonn
Head of the Clinical Electrophysiology Unit (ISCEV standard for Electroretinography,
Electro-Oculography, Visual Evoked Potentials)
Head of the Low-Vision-Center
7/31/2006 - 2/14/2010 Coordinator and Supervising Ophthalmologist of the Specialized Clinic Inherited Retinal
and Macular Diseases, Dept. of Ophthalmology, University of Bonn
9/28/2007 – 8/16/2008 Health Management: Advanced training, mibeg-Institute Medicine, Cologne
(www.mibeg.de); Certificate „Health Manager“
(1) Health Care Policy and Economy-related Framework of the Health System; (2)
Commercially-oriented Management; (3) Controlling; (4) Strategic and Organizational
Processes in Hospitals; (5) Quality Management; (6) Positioning of Health Care
Institutions in the Public; (7) Management Strategies for Physicians-in-Chief
3/1/2008 – 2/14/2010
Head of the Clinical Trial Center of the Dept. of Ophthalmology, Univ. of Bonn
„European Vision Institute – Clinical Trials – Sites of Excellence“ (EVI.CT.SE)
3/1/2010 – present
Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University Medical
School
Director of the Visual Neurophysiology Service (Johns Hopkins Hospital)
Director of the Retinal Degeneration Clinic (Retina Division, Wilmer Eye Institute)
12/1/2011 – present
The Dr. Frieda Derdeyn Bambas Professor of Ophthalmology (inaugural recipient),
Wilmer Eye Institute, Johns Hopkins University Medical School
RESEARCH ACTIVITIES
Peer Reviewed Original Science Publications
1. The AMD Gene Consortium, Fritsche LG et al. (2013) Seven new loci associated with age-related macular
degeneration. Nat Genet. 45: 433-9, 439e1-2.
2. Moshiri A, Scholl HPN, Canto-Soler MV & Goldberg MF (2013) A morphogenetic model for radial
streaking in the fundus of the carrier state of X-linked albinism. JAMA Ophthalmol. 131: 691-3.
3. Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TF, Peto T, Holz FG, Scholl HPN (2012) Macular
telangiectasia type 2. Prog Retin Eye Res. 34: 49-77.
4. Chen CJ, Scholl HPN, Birch DG, Iwata K, Miller NR, Goldberg MF (2012) Characterizing the phenotype
and genotype of a family with occult macular dystrophy. Arch Ophthalmol 130: 1554-9.
5. Fritsche LG, Fleckenstein M, Fiebig BS, Schmitz-Valckenberg S , Almut Bindewald-Wittich A, Keilhauer
CN , Renner AB, Mackensen F, Moessner A, Pauleikhoff D, Adrion C, Mansmann U, Scholl HPN, Holz FG
(2012) A subgroup of age-related macular degeneration is associated with mono-allelic mutations in the
ABCA4 gene. Invest Ophthalmol Vis Sci. 53: 2112-2118.
6. Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HPN, Charbel Issa P, Cano M, Brandstätter H,
Tsimikas S, Skerka C, Superti-Furga G, Handa JT, Zipfel PF, Witztum JL, Binder CJ (2011) Complement
factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478: 76-81.
7. Lauer N, Mihlan M, Hartmann A, Schlötzer-Schrehardt U, Keilhauer C, Scholl HPN, Charbel Issa P, Holz F,
Weber BH, Skerka C, Zipfel PF (2011) Complement regulation at necrotic cell lesions is impaired by the agerelated macular degeneration-associated factor-h his402 risk variant. J Immunol. 187: 4374-83.
2
8. Finger RP, Fenwick E, Marella M, Charbel Issa P, Scholl HPN, Holz FG, Lamoureux EL (2011) The relative
impact of vision impairment and cardiovascular disease on quality of life: The example of Pseudoxanthoma
elasticum. Health Qual Life Outcomes. 9(1): 113.
9. Finger RP, Charbel Issa P, Hendig D, Scholl HPN, Holz FG (2011) Monthly ranibizumab for choroidal
neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum: A one-year prospective study.
Am J Ophthalmol. 152: 695-703.
10. Finger RP, Fimmers R, Holz FG, Scholl HPN (2011) Incidence of blindness and severe visual impairment in
Germany - projections for 2030. Invest Ophthalmol Vis Sci. 52: 4381-9.
11. Finger RP, Fimmers R, Holz FG, Scholl HPN (2011) Prevalence and causes of registered blindness in the
largest federal state of Germany. Brit J Ophthalmol. 95: 1061-7.
12. Finger RP, Charbel Issa P, Schmitz-Valckenberg S, Holz FG, Scholl HPN (2011) Long-term effectiveness of
intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma
elasticum. Retina 31: in press.
13. Charbel Issa P, Finger RP, Kruse K, Baumüller S, Scholl HPN, Holz FG (2011) Monthly ranibizumab for
non-proliferative macular telangiectasia type 2: A 12-months prospective study: Am J Ophthalmol. 151: 876886.
14. Troeger E, Sliesoraityte I, Charbel Issa P, Scholl HPN, Zrenner E, Wilke R (2010) An integrated software
solution for multi-modal mapping of morphological and functional ocular data. Conf Proc IEEE Eng Med
Biol Soc. 2010: 6280-6283.
15. Charbel Issa P, Troeger E, Finger R, Holz FG, Wilke R, Scholl HPN (2010) Structure-function correlation of
the human central retina. PLoS One. 22;5(9): e12864.
16. Joshua A Szental JA, Baird PN, Richardson AJ, Islam FMA, Scholl HPN, Charbel Issa P, Holz FG, Gillies
M, Guymer RH (2010) Analysis of Glutathione S-Transferase Pi isoform (GSTP1) single nucleotide
polymorphisms and macular telangiectasia type 2. Int Ophthalmol. 30: 645-50.
17. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques
ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled
trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
Ophthalmology. 117: 1134-1146.e3.
18. Charbel Issa P, Finger RP, Götting C, Hendig D, Holz FG, Scholl HPN (2010) Centrifugal fundus
abnormalities in pseudoxanthoma elasticum. Ophthalmology. 117:1406-14.
19. Finger RP, Charbel Issa P, Kellner U, Schmitz-Valckenberg S, Fleckenstein M, Scholl HPN, Holz FG. (2010)
Spectral domain optical coherence tomography in adult-onset vitelliform macular dystrophy with cuticular
drusen. Retina 30: 1455-64.
20. Porz G, Scholl HPN, Holz FG, Finger RP (2010) Methoden zur Ermittlung persönlicher Krankheitskosten am
Beispiel retinaler Erkrankungen [Methods for estimating personal costs of disease using retinal diseases as an
example.] Ophthalmologe 107: 216-20.
21. Baumüller S, Charbel Issa P, Scholl HPN, Schmitz-Valckenberg S, Holz FG (2010) Outer retinal
hyperreflective spots on spectral-domain optical coherence tomography in macular telangiectasia type 2.
Ophthalmology 117: 2162-8.
22. Hecker LA, Edwards AO, Ryu E, Tosakulwong N, Baratz KH, Brown WL, Charbel Issa P, Scholl HPN,
Pollok-Kopp B, Schmid-Kubista KE, Bailey KR, Oppermann M (2010) Genetic control of the alternative
pathway of complement in humans and age-related macular degeneration. Hum Mol Genet. 19:209-15.
23. Finger RP, Porz G, Fleckenstein M, Charbel Issa P, Lechtenfeld W, Brohlburg D, Scholl HPN, Holz FG
(2010) The Retina Hotline – 18 months results from a telephone hotline for patients with retinal diseases.
Retina 30:635–639.
24. Scholl HPN, Fleckenstein M, Fritsche LG, Schmitz-Valckenberg S, Göbel A, Adrion C, Herold C, Keilhauer
CN, Mackensen F, Mößner A, Pauleikhoff A, Weinberger AWA, Mansmann U, Holz FG, Becker T, Weber
BHF (2009) CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of
geographic atrophy due to AMD. PLoS ONE 4:e7418.
3
25. Finger RP, Charbel Issa P, Ladewig M, Götting C, Holz FG, Scholl HPN (2009) Fundus autofluorescence in
patients with pseudoxanthoma elasticum. Retina 29: 1496-505.
26. Gillies MC, Zhu M, Chew E, Barthelmes D, Hughes E, Ali H, Holz FG, Scholl HPN Charbel Issa P (2009)
Familial asymptomatic macular telangiectasia type 2. Ophthalmology 116:2422-9.
27. Fleckenstein M, Adrion C, Schmitz-Valckenberg S, Göbel AP, Bindewald-Wittich A, Scholl HPN,
Mansmann U, Holz FG for the FAM Study group (2009) Concordance of disease progression in bilateral
geographic atrophy due to AMD. Invest Ophthalmol Vis Sci 51: 637-42.
28. Charbel Issa P, Holz FG, Scholl HPN (2009) Metamorphopsia in patients with macular telangiectasia type 2.
Doc Ophthalmol. 119:133-40.
29. Helb HM, Charbel Issa P, Fleckenstein M, Schmitz-Valckenberg S, Scholl HPN, Holz FG (2010) Clinical
evaluation of simultaneous confocal scanning laser ophthalmoscopy imaging combined with high-resolution,
spectral-domain optical coherence tomography. Acta Ophthalmol Scand. 88: 842-9.
30. Charbel Issa P, Finger RP, Holz FG, Scholl HPN (2009) Multimodal imaging including spectral domain OCT
and confocal near infrared reflectance for characterisation of outer retinal pathology in pseudoxanthoma
elasticum. Invest Ophthalmol Vis Sci. 50: 5913-8.
31. Charbel Issa P, Bolz HJ, Ebermann I, Domeier E, Holz FG, Scholl HPN (2009) Characterization of severe
rod-cone dystrophy in a consanguineous family with a splice site mutation in the MERTK gene. Brit J
Ophthalmol. 93: 920-5.
32. Schmitz-Valckenberg S, Fleckenstein M, Helb HM, Charbel Issa P, Scholl HPN, Holz FG (2009) In-vivo
imaging of foveal sparing in geographic atrophy secondary to age-related macular degeneration. Invest
Ophthalmol Vis Sci. 50: 3915-21.
33. Charbel Issa P, van der Veen RL, Stijfs A, Holz FG, Scholl HPN, Berendschot TTJM (2009) Quantification
of reduced macular pigment optical density in the central retina in macular telangiectasia type 2. Exp Eye Res.
89: 25-31.
34. Fleckenstein M, Charbel Issa P, Fuchs HA, Finger RP, Helb HM, Scholl HPN, Holz FG (2009) Discrete lines
of increased fundus autofluorescence in retinal dystrophies and functional correlate on microperimetry. Eye
(Lond) 23: 567-75.
35. Charbel Issa P, Scholl HPN, Gaudric A, Massin P, Kreiger AE, Schwartz S, Holz FG (2009) Macular fullthickness and lamellar holes in type 2 idiopathic macular telangiectasia. Eye 23: 435-41.
36. Finger RP, Charbel Issa P, Fimmers R, Holz FG, Rubin GS, Scholl HPN (2008) Reading performance is
reduced due to parafoveal scotomas in patients with macular telangiectasia type 2. Invest Ophthalmol Vis Sci.
50: 1366-70.
37. Fleckenstein M, Charbel Issa P, Helb HM, Schmitz-Valckenberg S, Scholl HPN, Holz FG (2008) Correlation
of lines of increased autofluorescence in macular dystrophy and pigmented paravenous retinochoroidal
atrophy by optical coherence tomography. Arch Ophthalmol. 126:1461-1463.
38. Pauleikhoff D, Scheider A, Wiedmann P, Gelisken F, Scholl HPN, Roider I, Mohr A, Zlateva G, Xu X.
(2008) Neovaskuläre altersabhängige Makuladegeneration in Deutschland. Beinträchtigung der
Lebensqualität und ihre finanziellen Auswirkungen [Neovascular age-related macular degeneration in
Germany: Encroachment on the quality of life and the financial implications.] Ophthalmologe 106: 242-51.
39. Scholl HPN, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B, Börncke F, Fritsche LG, Chong NV,
Fimmers R, Wienker T, Holz FG, Weber BHF, Oppermann M (2008) Systemic complement activation in agerelated macular degeneration. PLoS ONE 3(7): e2593.
40. Charbel Issa P, Finger RP, Holz FG, Scholl HPN (2008) Eighteen month follow-up of intravitreal
bevacizumab in type 2 idiopathic macular telangiectasia. Brit J Ophthalmol 92: 941-5.
41. Helb HM*, Charbel Issa P*, Berendschot TTJM, Scholl HPN, Holz FG (2008) Abnormal Macular Pigment
Distribution in Type 2 Macular Telangiectasia. Retina 28: 808-816.
4
42. Fleckenstein M, Charbel Issa P, Helb HM, Schmitz-Valckenberg S, Finger RP, Scholl HPN, Löffler KU,
Holz FG (2008) High resolution spectral domain-OCT imaging in geographic atrophy associated with agerelated macular degeneration. Invest Ophthalmol Vis Sci 49: 4137-4144.
43. Finger RP, Charbel Issa P, Ladewig M, Holz FG, Scholl HPN (2008) Intravitreal bevacizumab for choroidal
neovascularization associated with Pseudoxanthoma elasticum (PXE). Brit J Ophthalmol. 92: 483-7.
44. Charbel Issa P, Berendschot TTJM, Staurenghi G, Holz FG, Scholl HPN (2008) Confocal blue reflectance
imaging in type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci 49: 1172-7.
45. Meyer CH, Scholl HPN, Eter N, Helb HM, Holz FG (2008) Combined treatment of acute subretinal
haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a
retrospective pilot study. Acta Ophthalmol. 86: 490-4.
46. Charbel Issa P, Finger RP, Helb HM, Holz FG, Scholl HPN (2008) A new diagnostic approach in patients
with type 2 macular telangiectasia: confocal reflectance imaging. Acta Ophthalmol Scand 86:464-5.
47. Ladewig MS, Karl SE, Hamelmann V, Helb HM, Scholl HPN, Holz FG, Eter N. (2008) Combined
intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol. 246:17-25.
48. Charbel Issa P, Helb HM, Holz FG, Scholl HPN (2007) Correlation of macular function with retinal thickness
in nonproliferative type 2 idiopathic macular telangiectasia. Am J Ophthalmol. 145:169-175.
49. Charbel Issa P, Helb HM, Rohrschneider K, Holz FG, Scholl HPN (2007) Microperimetric assessment of
patients with type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci 48: 3788-3795.
50. Charbel Issa P, Holz FG, Scholl HPN (2007) Findings in fluorescein angiography and optical coherence
tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 114:
1736-1742.
51. Reinhard J, Messias A, Dietz K, MacKeben M, Lakmann R, Scholl HPN, Apfelstedt-Sylla E, Weber BHF,
Seeliger M, Zrenner E, Trauzettel-Klosinski S (2007) Quantifying fixation in patients with Stargardt disease.
Vision Research 47: 2076-85.
52. Ebermann I, Walger M, Scholl HPN, Charbel Issa P, Lüke C, Nürnberg G, Lang-Roth R, Becker C, Nürnberg
P, Bolz HJ (2007) Truncating mutation of the DFNB59 gene causes endocochlear hearing impairment and
central vestibular dysfunction. Hum Mutat. 28: 571-577.
53. Holz FG, Bindewald-Wittich A, Fleckenstein M, Dreyhaupt J, Scholl HPN, Schmitz-Valckenberg S, FAMStudy Group (2007) Progression of Geographic Atrophy and Impact of Fundus Autofluorescence Patterns in
Age-related Macular Degeneration. Am J Ophthalmol 143: 463-472.
54. Ebermann I, Scholl HPN, Charbel Issa P, Becirovic E, Lamprecht J, Jurklies B, Millan JM, Aller E, Mitter D,
Bolz H (2007) A novel gene for Usher syndrome type 2: mutations in the long isoform of whirlin are
associated with retinitis pigmentosa and sensorineural hearing loss. Hum Genet. 121: 203-211.
55. Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, Dreyhaupt J, Wolf S, Scholl HPN, Holz
FG for the Fundus Autofluorescence in Age-Related Macular Degeneration Study Group (2006) Correlation
between the Area of Increased Autofluorescence Surrounding Geographic Atrophy and Disease Progression
in Patients with AMD. Invest Ophthalmol Vis Sci 47: 2648-2654.
56. Scholl HPN, Kremers J, Besch D, Zrenner E, Jägle H (2005) Progressive cone dystrophy with deutan
genotype and phenotype. Graefes Arch Clin Exp Ophthalmol 244:183-191.
57. Dandekar SS, Jenkins SA, Peto T, Scholl HPN, Sehmi KS, Fitzke FW, Bird AC, Webster AR (2005)
Autofluorescence imaging of choroidal neovascularization due to age-related macular degeneration. Arch
Ophthalmol 123: 1507-1513.
58. Scholl HPN, Chong NHV, Robson AG, Holder GE, Moore AT, Bird AC (2004) Fundus autofluorescence in
patients with Leber congenital amaurosis. Invest Ophthalmol Vis Sci 45: 2747-2752.
59. Bellmann C, Neveu MM, Scholl HPN, Hogg CR, Rath PP, Jenkins S, Bird AC, Holder GE (2004) Localized
retinal electrophysiological and fundus autofluorescence imaging abnormalities in maternal inherited diabetes
and deafness. Invest Ophthalmol Vis Sci 45: 2355-2360.
5
60. Scholl HPN, Bellmann C, Dandekar SS, Bird AC, Fitzke FW (2004) Photopic and scotopic fine matrix
mapping of retinal areas of increased fundus autofluorescence in patients with age-related maculopathy.
Invest Ophthalmol Vis Sci 45: 574-583.
61. Scholl HPN, Dandekar SS, Peto T, Bunce C, Xing W, Jenkins S, Bird AC (2004) What is lost by digitizing
stereoscopic fundus color slides for macular grading in age-related maculopathy and degeneration?
Ophthalmology 111: 125-132.
62. Scholl HPN, Kremers J (2003) Alterations of L- and M-cone driven ERGs in cone and cone-rod dystrophies.
Vision Research 43: 2333-2344.
63. Kremers J, Stepien MW, Scholl HPN, Saito CA (2003) Cone selective adaptation influences L- and M-cone
driven signals in electroretinography and psychophysics. Journal of Vision 3: 146-160.
64. Scholl HPN, Kremers J (2003) L- and M-cone driven large-field and multifocal electroretinograms in sector
retinitis pigmentosa. Doc Ophthalmol 106: 171-181.
65. Jägle H, Sadowski B, Kremers J, Scholl HPN, Leo-Kottler B, Sharpe LT (2003) Detecting color vision in a
malingerer. Doc Ophthalmol 106: 121-128.
66. Scholl HPN, Peto T, Dandekar S, Bunce C, Xing W, Jenkins S, Bird AC (2003) Inter- and intra-observer
variability in grading lesions of age-related maculopathy and macular degeneration. Graefes Arch Clin Exp
Ophthalmol 241: 39-47.
67. Scholl HPN, Schuster AM, Vonthein R, Zrenner E (2002) Mapping of retinal function in Best macular
dystrophy using multifocal electroretinography. Vision Research 42: 1053-1061.
68. Scholl HPN, Besch D, Vonthein R, Weber BHF, Apfelstedt-Sylla E (2002) Alterations of slow and fast rod
ERG signals in patients with molecularly confirmed Stargardt disease type 1. Invest Ophthalmol Vis Sci 43:
1248-1256.
69. Scholl HPN, Langrová H, Pusch CM, Wissinger B, Zrenner E, Apfelstedt-Sylla E (2001) Slow and fast rod
ERG pathways in patients with X-linked complete stationary night blindness carrying mutations in the NYX
gene. Invest Ophthalmol Vis Sci 42: 2728-2736.
70. Kremers J, Scholl HPN (2001) Rod-/L-cone and rod-/M-cone interactions in electroretinograms at different
temporal frequencies. Visual Neuroscience 18: 339-351.
71. Scholl HPN, Kremers J (2001) Electroretinograms in S-cone monochromacy using S-cone and rod isolating
stimuli. Color Research and Application 26: S136-S139.
72. Scholl HPN, Kremers J, Wissinger B (2001) Macular Dystrophy with protan genotype and phenotype
studied with cone type specific ERGs. Current Eye Research 22: 221-228.
73. Scholl HPN, Langrová H, Weber BHF, Zrenner E, Apfelstedt-Sylla E (2001) Clinical electrophysiology of
two rod pathways: normative values and clinical application. Graefe's Arch Clin Exp Ophthalmol 239: 71-80.
74. Scholl HPN, Kremers J, Vonthein R, White K, Weber BHF (2001) L- and M-cone driven electroretinograms
in Stargardt's macular dystrophy-Fundus flavimaculatus. Invest Ophthalmol Vis Sci 42: 1380-1389.
75. Scholl HPN, Kremers J, Apfelstedt-Sylla E, Zrenner E (2000) L- and M-cone driven ERGs are differently
altered in Best's macular dystrophy. Vision Research 40: 3159-3168.
76. Scholl HPN, Kremers J (2000) Large phase differences between L-cone and M-cone driven
electroretinograms in retinitis pigmentosa. Invest Ophthalmol Vis Sci 41: 3225-3233.
77. Rivera A, White K, Stohr H, Steiner K, Hemmrich N, Grimm T, Jurklies B, Lorenz B, Scholl HPN,
Apfelstedt-Sylla E, Weber BHF (2000) A comprehensive survey of sequence variation in the ABCA4
(ABCR) gene in Stargardt disease and age-related macular degeneration. Am J Hum Genet 67: 800-813.
78. Kremers J, Scholl HPN, Knau H, Berendschot TTJM, Usui T, Sharpe LT (2000) L- and M-cone ratios in
human trichromats assessed by psychophysics, electroretinography and retinal densitometry. Journal of the
Optical Society of America A 17: 517-526.
79. Kremers J, Usui T, Scholl HPN, Sharpe LT (1999) Cone signal contributions to electroretinograms in
dichromats and trichromats. Invest Ophthalmol Vis Sci 40: 920-930.
6
Collaborative Study Publications (Role: Investigator):
80. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J,
Li XY, Whitcup SM; Ozurdex GENEVA Study Group, Li J (2011) Dexamethasone intravitreal implant in
patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.
Ophthalmology. 118: 2453-60.
81. Gangaputra S, Almukhtar T, Glassman AR, Aiello LP, Bressler N, Bressler SB, Danis RP, Davis MD;
Diabetic Retinopathy Clinical Research Network (2011) Comparison of film and digital fundus photographs
in eyes of individuals with diabetes mellitus. Invest Ophthalmol Vis Sci. 52: 6168-73.
82. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques
ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled
trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
Ophthalmology. 117: 1134-1146.e3.
Peer Reviewed Review Articles
1. Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TF, Peto T, Holz FG, Scholl HPN (2013) Macular
telangiectasia type 2. Prog Retin Eye Res. 34: 49-77.
2. Charbel Issa P, Chong NV, Scholl HPN (2011) The significance of the complement system for the
pathogenesis of age-related macular degeneration – current evidence and translation into clinical application.
Graefe's Arch Clin Exp Ophthalmol 249: 163-74.
3. Finger RP, Krohne TU, Charbel Issa P, Fleckenstein M, Scholl HPN, Holz FG (2009) Plasmapheresis for dry
age-related macular degeneration — evidence based? Retina 29: 569-72.
4. Finger RP, Charbel Issa P, Ladewig MS, Götting C, Szliska C, Scholl HPN, Holz FG (2009)
Pseudoxanthoma elasticum. Genetics, clinical manifestation and therapeutic approaches. Surv Ophthalmol.
54: 272-285.
5. Schmitz-Valckenberg S, Fleckenstein M, Scholl HPN, Holz FG (2009) Fundus autofluorescence and
progression of age-related macular degeneration. Surv Ophthalmol. 54: 96-117.
6. Finger RP, Fleckenstein M, Holz FG, Scholl HPN (2008) Quality of life in age-related macular degeneration
– a review of available vision-specific psychometric tools. Qual Life Res. 17: 559-74.
7. Finger RP, Scholl HPN, Holz FG (2008) Patient Reported Outcomes – Relevanz und Anwendung in der
Augenheilkunde [Patient reported outcomes. Relevance and application in ophthalmology]. Ophthalmologe
105: 722-726.
8. Scholl HPN, Fleckenstein M, Charbel Issa P, Keilhauer C, Holz FG, Weber BHF (2007) An update on the
genetics of age-related macular degeneration. Mol Vis 13: 196-205.
9. Finger RP, Fleckenstein M, Scholl HPN, Holz FG (2007) Pathophysiologie und Therapie der AMD:
Therapeutischer Anti-VEGF-Einsatz in der Augenheilkunde [Therapeutic anti-VEGF in ophthalmology:
pathophysiology and treatment of age-related macular degeneration]. Pharm Unserer Zeit. 36: 424-430.
10. Ladewig MS, Götting C, Szliska C, Charbel Issa P, Helb HM, Bedenicki I, Scholl HPN, Holz FG (2006)
Pseudoxanthoma elasticum. Ophthalmologe 103: 537-551.
11. Ladewig MS, Ziemssen F, Jaissle G, Helb HM, Scholl HPN, Eter N, Bartz-Schmidt KU, Holz FG (2006)
Intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmologe 103: 463-470.
12. Zrenner E, Cunha-Vaz J, Sahel JA, Sillito A, Scholl HPN, Wheeler-Schilling TH (2006) The European
Vision Institute. Opening up new frontiers?. Ophthalmologe 103:100-103.
13. Scholl HPN, Wheeler-Schilling TH, Zrenner E, Holz FG (2006) Establishing ophthalmology in the research
framework programs of the European Union. Ophthalmologe 103:91-99.
7
14. Holz FG, Bindewald-Wittich A, Schmitz-Valckenberg S, Eter N, Scholl HPN (2006) New perspectives in
the treatment of age-related macular degeneration. Dtsch Ärztebl C396-401.
15. Holz FG, Helb HM, Bindewald-Wittich A, Scholl HPN (2006) Modern pharmacotherapy of age-related
macular degeneration. Internist (Berl) 47:192-198.
16. Scholl HPN, Weber BHF, Nöthen MM, Wienker T, Holz FG (2005) Y402H polymorphism in complement
factor H and age-related macula degeneration. Ophthalmologe 102: 1029-1035.
17. Charbel Issa P, Scholl HPN, Holz FG, Oppermann M, Knolle P, Kurts C (2005) The complement system and
its possible role in the pathogenesis of age-related macular degeneration. Ophthalmologe 102:1036-1042.
18. Besch D, Jagle H, Scholl HPN, Seeliger MW, Zrenner E (2003) Inherited multifocal RPE-diseases:
mechanisms for local dysfunction in global retinoid cycle gene defects. Vision Research 43: 3095-3108.
19. Scholl HPN, Zrenner E (2000) Electrophysiology in the investigation of acquired retinal disorders. Surv
Ophthalmol 45: 29-47.
Extramural Sponsorship
Current Grants:
3/1/2010 - 2/28/2013
Structure-Function Correlation in Inherited Retinal Degenerations: Development of
Surrogate Endpoints for Clinical Trials
Wynn-Gund Translational Research Acceleration Program Enhanced Research and
Clinical Training Award
National Neurovision Research Institute (NNRI) – Foundation Fighting Blindness (FFB)
FFB Grant No: NNCD-CL-0310.0049-JHU-WG
Total: $510,000
PI: H.P.N. Scholl
1/1/2011 - 12/31/2015 “Ocular Albinism: Structure-Function Correlation of the Central Retina, PhenotypeGenotype Correlation and Interventional Therapy to Improve Visual Performance”
Ocular Albinism Research Fund: # 80026229
Clark Charitable Foundation, Inc.
Total: $3,676,000
PI: H.P.N. Scholl
1/1/2012 – 12/31/2015 Baylor-Johns Hopkins Center for Mendelian Genetics
PI: David Valle, M.D. (Hopkins); Co-investigator: James Lupski, M.D., Ph.D. (Baylor)
NHGRI/NIH
Total: $16,000,000
Collaborator
7/1/2012 - 6/30/2015
The ProgSTAR study (The Natural History of the Progression of Geographic Atrophy
Secondary to Stargardt’s Disease)
National Neurovision Research Institute (NNRI) – Foundation Fighting Blindness (FFB)
Total: $4,200,000 (Funding to the Wilmer Eye Institute/JHU: $1,343,686)
PI: H.P.N. Scholl
2/1/2013 – 1/31/2018
Eye and Vision Genomics Training Program: Institutional Research Training Grants
(T32) for Statistical Genetics and Genome Informatics.
PI: Dr. Terri Beaty, Bloomberg School of Public Health, Johns Hopkins University.
NIH Grant #: 1T32EY022303-01A1
Total: $800,856
Collaborator/Core Training Faculty Member
8
Pending
Investigator in the multi-investigator collaborative Bioengineering Partnership “Computational Model of the
Perception of Environments by People with Low Vision” with Johns Hopkins as the lead institution,
Exploratory/Developmental Bioengineering Research Grants (EBRG) [R21], NIH
PI: Dr. Robert Massof, Wilmer Eye Institute, Johns Hopkins University. Submitted to the NIH
Previous
1/1/2011 - 12/31/2012 Structure-Function Correlation in Macular Degeneration
Macular Degeneration Research Award
AHAF Grant No: M2010042
American Health Assistance Foundation (AHAF)
http://www.ahaf.org/research/grants/mdrcurrentawards.html?page=3
Total: $100,000
PI: H.P.N. Scholl
4/1/2008 - 3/31/2011
Work Package (WP) 2 “The Ageing Eye”
European Commission: Collaborative Project “EuroVisionNet”
EU FP7 HEALTH-2007-200641
http://www.eurovisionnet.eu/
Total: EUR 795.000 ($1,130,252) / Own Sub-Project (WP2): EUR 58,500 ($83,169)
WP Leader: H.P.N. Scholl
10/1/2005 - 2/14/2010 Natural History Study of Macular Telangiectasia Type 2
The Mac Tel Foundation/Lowy Medical Research Institute, Sydney
EUR 226,461 ($321,960)
PI: F.G. Holz & H.P.N. Scholl
Co-PI (50%)
9/1/2008 - 8/31/2009
Complement protein marker for age-related macular degeneration [KomplementProteinmarker für die altersabhängige Makuladegeneration]
bonfor O_1370011
Medical Faculty, University of Bonn
EUR 62,100 ($39,253)
PI: P. Charbel Issa, F.G. Holz & H.P.N. Scholl; Co-PI (33%)
7/1/2009 - 6/30/2011
Molecular diagnostics of AMD [Molekulare Diagnostik der AMD]
MODIAMD; BMBF MBT_011
Federal Ministry for Education and Research [Bundesministerium für Bildung und
Forschung] BMBF MoBiTech-Initiative
Total: EUR 3,700,000 ($5,260,000) / Own Sub-Project: EUR 500,000 ($710,850)
PI: S. Schmitz-Valckenberg, H.P.N. Scholl (until 2/14/2010) & F.G. Holz
1/1/2000 – 12/31/2000 Physiologic and pathophysiologic signal flow of cone types and their interaction in the
human electroretinogram [Physiologischer und pathologischer Signalfluß von
Zapfentypen und deren Interaktion im Elektroretinogramm (ERG)]
fortüne 707-0-0
Medical Faculty, University of Tübingen)
EUR 66,928 ($95,152)
PI: H.P.N. Scholl
1/1/2001 – 12/31/2001 Physiologic and pathophysiologic signal flow of cone types and their interaction in the
human electroretinogram [Physiologischer und pathologischer Signalfluß von
Zapfentypen und deren Interaktion im Elektroretinogramm (ERG)]
fortüne 707-0-1
9
Medical Faculty, University of Tübingen
EUR 27,610 ($39,253)
PI: H.P.N. Scholl
10/1/2001 - 09/30/2003 DFG Research Fellowship
Awarded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)
DFG SCHO 734/1
EUR 63,731 ($90,606)
1/1/2004 - 12/31/2006 PHOTAGE „Photoreceptor Dynamics in Age-Related Macular Degeneration.
Consequences for early diagnosis“
EU FP5 QLRT-2001-02494
European Commission: Concerted Action
Total: EUR 81,600 ($115,158) / Own Sub-Project: EUR 33,600 ($47,769)
Coordinator: H.P.N. Scholl
1/1/2004 - 12/31/2006 DFG Heisenberg Fellowship
Awarded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)
DFG SCHO 734/2
EUR 143,940 ($204,639)
4/1/2005 - 3/31/2009
Work Package (WP) 1 “Phenotyping, tissue and DNA collection in patients with agerelated macular disease”
EU FP6 LSHG-CT-2005-512036
European Commission: Integrated Project EVI-GENORET (“Functional Genomics of the
Retina in Health and Disease”)
http://www.evi-genoret.org/
Total: EUR 10,000,000 ($14,217,000) / Own Sub-Project (WP2): EUR 206,720
($293,894)
Coordinator: J.A. Sahel
WP1 Leader: H.P.N. Scholl
4/1/2005 – 10/28/2005 International evaluation of the burden of illness of exudative age-related macular
degeneration (AMD)
Sponsor: PFIZER, Inc.
EUR 1,024 ($1,456)
Center Coordinator/PI: H.P.N. Scholl
3/1/2006 – 02/28/2007 Investigation of the complement system in AMD pathogenesis using
immunohistochemistry, flow cytometry and serology [Aufklärung der Bedeutung des
Komplementsystems für die AMD-Pathogenese mit immunhistologischen,
durchflußzytometrischen und serologischen Methoden]
Pro-Re//Seed/Issa.1
Pro Retina Deutschland (Germany)
EUR 38,500 ($54,735)
PI: P. Charbel Issa, F.G. Holz & H.P.N. Scholl
Co-PI (33%)
9/1/2006 – 8/31/2007
Genotype-Phenotype Correlation in geographic atrophy due to age-related macular
degeneration [Genotyp-Phänotyp-Korrelation bei AMD-Patienten mit geographischer
Atrophie]
German Ophthalmological Society (Deutsche Ophthalmologische Gesellschaft, DOG)
EUR 25,000 ($35,543)
PI: M. Fleckenstein, H.P.N. Scholl & F.G. Holz
Co-PI (33%)
1/1/2007 – 12/31/2007 Microperimetric assessment of patients with Macular Telangiectasia Type 2
Investigator-Initiated Trial (IIT); Sponsor: Dept. of Ophthalmology, University of Bonn;
10
Lowy Medical Research Institute, Sydney
EUR 40,000 ($56,868)
Co-PI (50%)
1/1/2007 – 12/31/2007 Fundus autofluorescence imaging and macular pigment distribution in Macular
Telangiectasia Type 2
Lowy Medical Research Institute, Sydney
EUR 40,000 ($56,868)
Co-PI (50%)
8/1/2007 – 7/31/2008
The complement system in age-related macular degeneration
Ernst-Elfriede Griebel Stiftung (Germany)
EUR 15,000 ($21,326)
PI: P. Charbel Issa, F.G. Holz & H.P.N. Scholl
Co-PI (33%)
1/1/2008 – 12/31/2008 Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)
NOVARTIS, Basel
ClinicalTrials.gov # NCT00504400; Paul-Ehrlich-Institut, CRFB002ADE04; EudraCT #
2006-006233-40
EUR 39,6000 ($56,299)
Co-PI (50%)
1/1/2008 – 12/31/2008 Ranibizumab to Treat CNVs in Patients With PXE
NOVARTIS, Basel
ClinicalTrials.gov # NCT00510965; Paul-Ehrlich-Institut, CRFB002ADE03; EudraCT #
2006-006233-49
EUR 39,6000 ($56,299)
Co-PI (50%)
Research Program Building / Leadership
7/1/1997 – 9/30/2001
Head of the Laboratory for Cone Type Specific Electroretinography (Dept. of
Ophthalmology, University of Tübingen).
10/1/2004 – 2/14/2010 Research Coordinator, Dept. of Ophthalmology, Univ. of Bonn.
10/1/2004 – 2/14/2010 Co-PI of the Research group on Advanced Phenotyping and Genotype-Phenotype
Correlation in Retinal Degenerations at the Dept. of Ophthalmology, University of Bonn.
4/1/2005 – 2/14/2010
PI of the Research group on Genotyping, Phenotyping and Proteomics in Age-related
Macular Degeneration (AMD) in conjunction with the European Integrated Project EVIGENORET (“Functional Genomics of the Retina in Health and Disease”).
3/1/2008 – 2/14/2010
„European Vision Institute – Clinical Trials – Sites of Excellence“ (EVI.CT.SE).
3/1/2010 – present
Director, Visual Neurophysiology Service, The Johns Hopkins Hospital
3/1/2010 – present
PI of the Research Program on Structure-Function Correlation in Retinal and Macular
Degenerations (Foundation Fighting Blindness, American Health Assistance Foundation).
1/1/2011 – present
PI of the Research Program on Ocular Albinism (Clark Charitable Foundation, Inc.)
11
1/1/2012 – present
Collaborator in the Baylor-Johns Hopkins Center for Mendelian Genetics
PI: Dr. David Valle (Johns Hopkins University
PI of the Research Program “The Genetics and Proteomics of Inherited Ophthalmic
Diseases” at the Wilmer Eye Institute, Johns Hopkins University
7/1/2012 – present
PI of the ProgSTAR study (The Natural History of the Progression of Geographic
Atrophy Secondary to Stargardt’s Disease; Collaborative Network of the National
Neurovision Research Institute (NNRI)
EDUCATIONAL ACTIVITIES
Educational Publications
Invited review articles
1. Finger RP, Hendig D, Götting C, Charbel Issa P, Zarbock R, Scholl HPN, Holz FG (2011) Patient mit
langjährigem Hochdruck, PAVK und faltigem Hals. Warum muss er unbedingt zum Augenarzt? MMWFortschr. Med. 153(7): 38-39.
2. Scholl HPN (2008) Systemische Komplementaktivierung bei der altersabhängigen Makuladegeneration.
DZKF 11/12-2008: 53-55.
3. Scholl HPN (2008) Therapeutische Konsequenzen der genetischen Faktoren bei der altersabhängigen
Makuladegeneration. Z prakt Augenheilkd 29: 355-358.
4. Scholl HPN (2008) Das Komplementsystem bei der altersabhängigen Makuladegeneration: Von Genen über
Proteine zur Therapie. Ophthalmologische Nachrichten 10/2008: in press.
5. Charbel Issa P, Holz FG, Scholl HPN (2008) Systemische Komplementaktivierung bei der altersabhängigen
Makuladegeneration. Ophthalmologische Nachrichten 09/2008: 9.
6. Scholl HPN, Fleckenstein M, Schmitz-Valckenberg S, Charbel Issa P, Holz FG (2008) Neue Ansätze zur
Diagnostik und Therapie von Netzhauterkrankungen. Augenspiegel 54: 12-16.
7. Schmitz-Valckenberg S, Fleckenstein M, Scholl HPN, Holz FG (2008) Therapieansätze bei atrophischer
altersabhängiger Makuladegeneration. Z prakt Augenheilkd 29: in press.
8. Scholl HPN (2008) Die therapeutischen Möglichkeiten bleiben zunächst begrenzt. Stargardtsche
Makuladystrophie – Molekulargenetik und Knock-out-Tiermodelle lassen auf Erfolge hoffen.
Ophthalmologische Nachrichten 03/2008: 14-16.
9. Fleckenstein M, Finger RP, Charbel Issa P, Scholl HPN, Holz FG (2008) VEGF Trap-Eye. Ein neuer
Therapieansatz bei feuchter AMD. Pro Retina Aktuell 107: 3.
10. Finger RP, Scholl HPN, Holz FG (2008) AMD und Lebensqualität. Zum Stellenwert der Prävention und
Rehabilitation.. Augenspiegel 54: 10-12.
11. Scholl HPN (2007) Genetische Faktoren der AMD. Ophthalmologische Nachrichten 10/2007: 19-20.
12. Finger RP, Scholl HPN, Holz FG (2007) Intravitreales Ranibizumab zur Therapie von chorioidalen
Neovaskularisationen bei Pseudoxanthoma elasticum. PXE Report 7: 4-5.
13. Finger RP, Scholl HPN, Holz FG (2007) Einsichten in die Erkrankungsentstehung – durch die
Gewebespende. PXE Report 7: 6.
14. Scholl HPN (2007) Genetik der altersabhängigen Makuladegeneration – neue Perspektiven. Z prakt
Augenheilkd 28: 359-361.
15. Scholl HPN, Holz FG (2007) Genetische Faktoren der AMD. Augenspiegel 53: 16-17.
16. Holz FG, Helb HM, Bindewald-Wittich A, Fleckenstein M, Scholl HPN (2006) Pharmakotherapie der
altersabhängigen Makuladegeneration. Z prakt Augenheilkd 26: 265-274.
12
17. Scholl HPN, Fleckenstein M, Krohne T, Helb HM, Charbel Issa P, Holz FG (2006) Interdisziplinärer Dialog
beim Pro Retina Research-Colloquium. Augenspiegel 52: 8-10.
18. Charbel Issa P, Scholl HPN, Holz FG (2005) Internationale Studie zu makulären Teleangiektasien. Pro Retina
Aktuell 98: 9-10.
Editorials
1. Scholl HPN, Zrenner E (2006) Europäische Forschungsförderung in der Ophthalmologie. Ophthalmologe
103:89-90.
2. Holz FG, Scholl HPN (2005) Komplementfaktor H und die altersabhängige Makuladegeneration. Neue
Erkenntnisse - und Herausforderungen. Ophthalmologe 102:1027-1028.
Case Reports
1. Finger RP, Charbel Issa P, Holz FG, Scholl HPN (2010) A case of diffuse fluorescein leakage not associated
with a CNV in Pseudoxanthoma Elasticum. Eye (Lond) 24: 1111-3.
2. Charbel Issa P, Fleckenstein M, Scholl HPN, Holz FG, Meyer CH (2009) Confocal scanning laser
ophthalmoscopy findings in chronic solar retinopathy. Ophthalmic Surg Lasers Imaging 39:497-499.
3. Charbel Issa P, Foerl M, Helb HM, Scholl HPN, Holz FG (2008) Multimodal fundus imaging in foveal
hypoplasia: combined scanning laser ophthalmoscope imaging and spectral-domain optical coherence
tomography. Arch Ophthalmol 126:1463-1465.
4. Charbel Issa P, Scholl HPN, Holz FG (2007) Intravitreal bevacizumab for the treatment of type 2 idiopathic
macular telangiectasis. Retinal Cases & Brief Reports 1:79-81.
5. Charbel Issa P, Scholl HPN, Helb HM, Fleckenstein M, Inhetvin-Hutter C, Holz FG (2007) Unilaterale
pigmentierte paravenöse retinochorioidale Atrophie [Unilateral pigmented paravenous retinochoroidal
atrophy]. Klin Monatsbl Augenheilkd. 224:791-793.
6. Scholl HPN, Thiel HJ, Schlote T (1999) Orbitablutung als Folge einer Heparin-induzierten
Thrombozytopenie [Orbital hemorrhage as a sequela of heparin-induced thrombocytopenia]. Klin Monatsbl
Augenheilkd 215: 197-200.
Letters, correspondence
1. Finger RP, Krohne TU, Issa PC, Scholl HPN, Holz FG (2010) No evidence to support the use of
plasmapheresis for age-related macular degeneration. Ther Apher Dial. 14: 607-8.
2. Charbel Issa, P, Holz FG, Scholl HPN (2009) Correspondence to: Kovach JL, Rosenfeld PJ (2008)
Bevacizumab (Avastin) therapy for idiopathic macular telangiectasia type 2. Retina 29: 717-8.
3. Charbel Issa, P, Holz FG, Scholl HPN (2008) Juxtafoveal telangiectasis. Ophthalmology 115: 1636.
Book Chapters, Monographs
1. Fletcher EC, Scholl HPN (2013) Ophthalmic disease in the ageing society. In: Scholl HPN, Massof RW,
West SK, eds. Ophthalmology and the Ageing Society (Essentials in Ophthalmology; Singh AD, series
editor). Heidelberg New York Dordrecht London: Springer: 1-12.
2. Finger RP, Scholl HPN (2013) Blindness and visual impairment: high-income countries. In: Scholl HPN,
Massof RW, West SK, eds. Ophthalmology and the Ageing Society (Essentials in Ophthalmology; Singh AD,
series editor). Heidelberg New York Dordrecht London: Springer: 19-32.
13
3. Charbel Issa P, Chong NV, Scholl HPN (2012) The Complement system and age-related macular
degeneration. In: Holz FG, Pauleikhoff D, Spaide RF, Bird AC, eds. Age-Related Macular Degeneration. 3rd
edition. Berlin Heidelberg New York: Springer: 65-76.
4. Charbel Issa P, Chong NV, Scholl HPN (2011) Das Komplementsystem bei der altersabhängigen
Makuladegeneration. In: Die altersabhängige Makuladegeneration. 3. Aufl. Hrsg. von Holz FG, Pauleikhoff
D, Spaide RF, Bird AC. Berlin Heidelberg New York: Springer: 65-78.
5. Scholl HPN, Wabbels B (2009) Fundus autofluorescence in Leber congenital amaurosis. In: Lois N &
Forrester J, eds. Fundus Autofluorescence Imaging. Lippincott, 175-183.
6. Scholl HPN, Charbel Issa P, Holz FG (2009) Ätiologie und Pathogenese der altersabhängigen
Makuladegeneration (AMD). In: Die altersabhängige Makuladegeneration. 2. Aufl. Hrsg. von Eter N. UNIMED Verlag, Bremen, London, Boston: 13-24.
7. Schmitz-Valckenberg S, Fleckenstein M, Bindewald-Wittich A, Scholl HPN, Holz FG (2009) Fundus
autofluorescence in atrophic age-related macular degeneration. In: Lois N & Forrester J, eds. Fundus
Autofluorescence Imaging. Lippincott, 131-139.
8. Scholl HPN, Charbel Issa P, Fleckenstein M, Schmitz-Valckenberg S, Holz FG (2009): Age-related Macular
Degeneration. In: Encyclopedia of Molecular Mechanisms of Disease. Hrsg. von Lang F. Berlin Heidelberg
New York: Springer, 1244-1247.
9. Charbel Issa P, Scholl HPN, Finger RP, Meyer CH, Holz FG (2008) Pharmacotherapy in Macular
telangiectasia; In: Nguyen QD, Rodrigues EB, Farah ME, Mieler WF, eds. Retinal Pharmacotherapy,
Elsevier, 181-185.
10. Charbel Issa P, Scholl HPN, Finger RP, Meyer CH, Holz FG (2009) Pharmacotherapy in Macular
telangiectasia; In: Nguyen QD, Rodrigues EB, Farah ME, Mieler WF, eds. Retinal Pharmacotherapy, Elsevier
[in press]
11. Fleckenstein M, Scholl HPN, Holz FG (2007) Discrete lines of increased fundus autofluorescence in various
forms of retinal dystrophies. In: Holz FG, Schmitz-Valckenberg S, Spaide RF, Bird AC , eds. Atlas of Fundus
Autofluorescence Imaging. Berlin Heidelberg New York: Springer, 121-132.
12. Schmitz-Valckenberg S, Helb HM, Bindewald-Wittich A, Scholl HPN, Holz FG (2007) Age-related macular
degeneration II – Geographic atrophy. In: Holz FG, Schmitz-Valckenberg S, Spaide RF, Bird AC , eds. Atlas
of Fundus Autofluorescence Imaging. Berlin Heidelberg New York: Springer, 147-163.
13. Charbel Issa P, Scholl HPN, Helb HM, Holz FG (2007) Idiopathic macular telangiectasia. In: Holz FG,
Schmitz-Valckenberg S, Spaide RF, Bird AC , eds. Atlas of Fundus Autofluorescence Imaging. Berlin
Heidelberg New York: Springer, 199-205.
14. Charbel Issa P, Scholl HPN, Helb HM, Holz FG (2007) Idiopathic macular telangiectasia. In: Holz FG,
Spaide RF, eds. Medical Retina. Berlin Heidelberg New York: Springer, 183-197.
15. Schmitz-Valckenberg S, Fleckenstein M, Scholl HPN, Holz FG (2007) New perspectives in geographic
atrophy associated with AMD. In: Holz FG, Spaide RF, eds. Medical Retina. Berlin Heidelberg New York:
Springer, 114-129.
16. Scholl HPN, Fleckenstein M, Charbel Issa P, Keilhauer C, Holz FG, Weber BHF (2007) Genetics of agerelated macular degeneration: update. In: Holz FG, Spaide RF, eds. Medical Retina. Berlin Heidelberg New
York: Springer, 35-52.
17. Scholl HPN, Bindewald-Wittich A, Charbel Issa P, Schmitz-Valckenberg S, Holz FG (2006) Ätiologie und
Pathogenese der altersabhängigen Makuladegeneration. In: Choroidale Neovaskularisation bei
altersabhängiger Makuladegeneration. Hrsg. von Eter N. UNI-MED Verlag, Bremen, London, Boston: 14-25.
18. Eter N, Bindewald-Wittich A, Scholl HPN, Holz FG (2006) Chirurgische Therapie bei altersabhängiger
Makuladegeneration. In: Choroidale Neovaskularisation bei altersabhängiger Makuladegeneration. Hrsg. von
Eter N. UNI-MED Verlag, Bremen, London, Boston: 72-79.
19. Holz FG, Scholl HPN (2006) Netzhaut: Angewandte Anatomie und klinische Untersuchung. In:
Facharztprüfung Augenheilkunde. Hrsg. von Kampik A, Grehn F & Messmer EM. Thieme Verlag, Stuttgart:
115.
14
20. Holz FG, Scholl HPN (2006) Makulafunktionsteste bei trüben Medien. In: Facharztprüfung Augenheilkunde.
Hrsg. von Kampik A, Grehn F & Messmer EM. Thieme Verlag, Stuttgart: 115.
21. Holz FG, Scholl HPN (2006) Fluoreszenzangiographie. In: Facharztprüfung Augenheilkunde. Hrsg. von
Kampik A, Grehn F & Messmer EM. Thieme Verlag, Stuttgart: 116-117.
22. Scholl HPN, Holz FG (2006) Altersabhängige Makuladegeneration. In: Springer Lexikon Diagnose &
Therapie. Springer Medizin Verlag, Heidelberg: 961-966.
23. Bindewald A, Roth F, Schmitz-Valckenberg S, Scholl HPN, Holz FG (2005) Fundus autofluorescence
imaging; In: Holz FG, Spaide RF, eds. Medical Retina. Berlin Heidelberg New York: Springer, 19-34.
24. Kremers J, Scholl HPN, Usui T, Zrenner E (1999) Differenzierung unterschiedlicher Zapfensysteme mit dem
Elektroretinogramm und Aufdeckung selektiver Schädigungsmuster; In: Zrenner E, ed. Sichtweisen.
Entwicklungen in den Jahren 1994-1998. Tübingen: 64-65.
25. Scholl HPN, Zrenner E (1995). Motion thresholds of coloured stimuli of different luminance contrasts are
increased in ocular hypertension and early primary-open-angle-glaucoma (POAG). In Drum,B.A. (ed),
Colour vision deficiencies XII (pp. 73-85). Dordrecht: Kluwer Academic Publishers.
Whole Books/Textbooks
1. Scholl HPN (1997) Abhängigkeit der Bewegungsempfindlichkeit vom Helligkeitskontrast zweier Farben
beim frühen Glaukom und bei okulärer Hypertension. (Univ. Diss. Tübingen) Knirsch Verlag,
Kirchentellinsfurt. (ISBN 3927091375)
2. Scholl HPN (2005) Photoreceptor type-specific electroretinography in inherited retinal disorders. Books on
Demand, Norderstedt. (ISBN-10: 3833419709; ISBN-13: 978-3833419706)
3. Scholl HPN, Massof RW, West SK (2013) Ophthalmology and the Ageing Society (Essentials in
Ophthalmology; Singh AD, series editor). Heidelberg New York Dordrecht London: Springer. (ISBN-10:
3642363237; ISBN-13: 978-3642363238)
Teaching
Classroom instruction
1997 – 1999
1997 – 2001
1997 – 2001
1998 – 2001
1998 – 2001
1998 – 2001
1998 – 2001
1999 – 2000
1999 – 2001
Basic Science Course “Function and Structure of the Visual System” (30%), instructor for
ophthalmologists, Dept. of Pathophysiology of Vision and Neuroophthalmology, University Eye
Hospital Tübingen
Seminar “Basic Principles of Clinical Electrophysiology of Vision” (10%), instructor for
residents, Dept. of Pathophysiology of Vision and Neuroophthalmology, University Eye Hospital
Tübingen
Seminar “Physiological, Psychophysical and Clinical Aspects of the Visual System” (10%),
lecturer for medical students, Dept. of Pathophysiology of Vision and Neuroophthalmology,
University Eye Hospital Tübingen
Clinical Course “Ophthalmology (Patient Demonstration)”, instructor for medical students, Dept.
of Ophthalmology, University of Tübingen
Seminar “Color Vision” (20%), lecturer for medical students, Dept. of Pathophysiology of Vision
and Neuroophthalmology, University Eye Hospital Tübingen
Practical Course “Physiology and Pathophysiology of the Visual System” (20%), instructor for
medical students, Department of Experimental Ophthalmology, University of Tübingen
Seminar “Inherited Retinal Dystrophies” (40%), lecturer for residents, Dept. of Pathophysiology
of Vision and Neuroophthalmology, University Eye Hospital Tübingen
Seminar “Physiology of the Retina” (15%), lecturer for residents, Dept. of Pathophysiology of
Vision and Neuroophthalmology, University Eye Hospital Tübingen
Seminar “The Eye and I – Neural Sciences in Clinical Ophthalmology” (20%), lecturer for
15
1999 – 2001
2004 – 2010
2004 – 2010
2004 – 2010
2005 – 2010
2005 – 2008
2006 – 2008
2008 – 2010
residents, Dept. of Ophthalmology, University of Tübingen
Core Course “Visual System” (50%), instructor for PhD students, Graduate School of Neural and
Behavioural Sciences, University of Tübingen
Practical Course “Principles of Ophthalmic Examination” (15%), lecturer and instructor for
medical students, Dept. of Ophthalmology, University of Bonn
Lecture Series “Clinical Ophthalmology” (10%), lecturer for medical students, Dept. of
Ophthalmology, University of Bonn
Core Clinical Course “Clinical Ophthalmology” (10%), instructor for medical students, Dept. of
Clinical Course “Clinical Ophthalmology II” (15%), instructor for medical students in final year
[Praktisches Jahr, PJ], Dept. of Ophthalmology, University of Bonn
Course “Experimental Ophthalmology” (30%), instructor for medical students, Dept. of
Integrated Seminar “Anatomy, Physiology, Ophthalmology” (30%), instructor for (pre-clinical)
medical students, University of Bonn
Elective “Diagnostics and Therapy of Retinal Diseases” (50%), instructor for medical students,
2010 – 2012
Residents in Ophthalmology Lecture: “Electrophysiology of retinal disease: a diagnostic and
monitoring tool”, Wilmer Eye Institute, Johns Hopkins University.
2010 – 2012
Residents in Ophthalmology Lecture: “Retinal and Macular Dystrophies”, Wilmer Eye Institute,
Johns Hopkins University.
2011 – 2012
Residents in Ophthalmology Lecture: “Optical Coherence Tomography – Clinical Application”,
Wilmer Eye Institute, Johns Hopkins University; together with Dr. Quan Nguyen.
2011 – present Genes to Society (GTS) program for Johns Hopkins medical students. Lecture: “Age-related
Macular Degeneration”
2012
Course “Cellular and molecular biology of photoreceptors in health and disease". Lecture:
“Clinical aspects of retinal degeneration”; Seminar: “New therapeutic approaches for retinal
degenerations due to mutations of genes implicated in the visual cycle”.
2013
Didactic Course for Residents in Ophthalmology: “Retinal Degenerations and Retinal
Dystrophies” (Retina Subspecialty Grand Rounds, Lecture, Seminar); Practical Course in Visual
Neurophysiology
Clinical instruction
2004 – 2010
Outpatient service for patients with retinal diseases, including specialized clinics for patients with
age-related macular degeneration and inherited retinal and macular dystrophies. Attending
physician, Dept. of Ophthalmology, Univ. of Bonn.
2004 – 2010
Inpatient service Vitreoretinal Surgery. Attending vitreoretinal surgeon, Dept. of Ophthalmology,
Univ. of Bonn.
2010 – present Outpatient service: Retinal Degeneration Center, Wilmer Eye Institute, Johns Hopkins Medicine
2010 – present Vitreoretinal Surgery: Wilmer Eye Institute, Johns Hopkins Medicine
Mentoring
Advisees
2005 – 2009
Peter Charbel Issa, MD, clinical fellow, currently Marie Curie Intra-Research Fellow at the
Nuffield Laboratory of Ophthalmology, University of Oxford, UK (Marie Curie Intra-European
Fellowship EU-FP7-237238), mentor.
16
2005 – 2010
MD thesis of Arno Göbel: Correlation of progression rate of geographic atrophy due to agerelated macular degeneration and genetic variants in the complement factor H and LOC3877715
genes [Korrelation der Progressionsgeschwindigkeit der geographischen Atrophie als Unterform
der späten altersabhängigen Makuladegeneration und genetischen Variationen im Komplement
Faktor H-Gen und dem LOC387715-Gen], co-mentor.
2006 – 2009
MD thesis of Stefanie Janzer: Investigation of the role of the complement system in the
pathogenesis of age-related macular degeneration [Aufklärung der Bedeutung des
Komplementsystems für die Pathogenese der altersabhängigen Makuladegeneration mit
serologischen Methoden], mentor.
2006 – 2010
Robert P. Finger, MD, MIH, clinical fellow at the Dept. of Ophthalmology, University of Bonn,
currently DFG Research Fellow at the Center for Eye Research Australia (CERA; Melbourne,
Australia), mentor.
2007 – 2010
MD thesis of Kathrin Kruse: Intravitreal Ranibizumab for macular telangiectaisa type 2
[Intravitreales Ranibizumab zur Behandlung von makulären Teleangiektasien vom Typ 2],
mentor.
2011 – present Kristen Bowles, OD, Clinical Research Fellow (previously: National Eye Institute, NIH):
Structure-Function Correlation in Stargardt’s Disease – Development of Surrogate Endpoints for
Clinical Trials, mentor.
2011 – present Emily Fletcher, MD, Clinical Research Fellow (previously: Oxford University, UK): StructureStructure-Function and Phenotype Genotype correlation of the central retina in ocular albinism,
with interventional therapy to improve visual performance, mentor. Dr. Fletcher is the recipient of
the Clinical/Research Fellowship Award in Inherited Orphan Retinal Degenerations 2011 of the
Foundation Fighting Blindness.
2011
The Hendrik Scholl Research Grant Award
awarded to: Hongting Liu
Assessment of Visual Fixation and Central Retinal Sensitivity in Normal Subjects and Subjects
with Maculopathy Using Two Types of Microperimetry Devices
Mentor: Hendrik Scholl, Diana Do & Quan Nguyen
Sponsor: Hendrik Scholl
2012 – present Rupert W. Strauss, MD, Clinical Research Fellow (previously: Eye Hospital AKH Linz/Dept. of
Ophhalmology, Medical University Graz, Austria): The ProgSTAR study (The Natural History of
the Progression of Geographic Atrophy Secondary to Stargardt’s Disease), mentor.
2012 – present Yulia Wolfson, MD, Clinical Research Fellow (previously: Department of Ophthalmology,
Carmel Medical Center, Haifa, Israel): Interventional Trial in Albinism, mentor.
2013 – present Millena Bittencourt, MD, Clinical Research Fellow: Clinical Trials in Retinal Degenerations,
mentor.
2013 – present Rachel Annam, MD, MPH, Clinical Research Fellow (previously: Johns Hopkins Bloomberg
School of Public Health): Clinical Trials in Retinal Degenerations, mentor.
2013 – present Voraporn Chaikitmongkol, MD, Clinical Research Fellow (previously: Department of
Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand): Visual
Neurophysiology, mentor.
Educational Program Building/Leadership
2008 – 2010
Coordinator of the Elective “Diagnostics and Therapy of Retinal Diseases” for medical students,
17
Educational Extramural Funding
3/20-21/2009
“The Ageing Eye Conference”
European Commission: Collaborative Project “EuroVisionNet”
EU FP7 HEALTH-2007-200641
http://www.eurovisionnet.eu/news/news-ageingeye_2009.html;
http://www.vision-research.eu/index.php?id=429
EUR 58,500 ($83,169)
Organizer and Conference Chair
CLINICAL ACTIVITIES
Certification
Medical, other state/government licensure
1999 – present Baden-Württemberg, Germany
2001 – 2003
General Medical Council, London, United Kingdom, W1W 5JE, UK; GMC No 6035819
2010 – present Medical Licence by Conceded Eminence, Board of Physicians, State of Maryland
(D0048402; 4/28/2010 – 9/30/2011)
Clinical (Service) Responsibilities
2004 – 2010
Inpatient service Vitreoretinal Surgery, attending vitreoretinal surgeon, Dept. of
Ophthalmology, Univ. of Bonn.
2004 - 2010
Outpatient clinic for Retinal Diseases including Age-related Macular Degeneration,
attending, 1½ days/week, Dept. of Ophthalmology, Univ. of Bonn.
2006 - 2010
Specialized clinic for Inherited Retinal and Macular Diseases, coordinator and
supervising ophthalmologist, 1 day/week, Dept. of Ophthalmology, Univ. of Bonn.
07/2010 – present
Head of the Retinal Degeneration Center: Specialized clinic for Inherited Retinal
Degenerations, 2 clinics/week, Wilmer Eye Institute, Johns Hopkins University
07/2010 – present
Vitreoretinal Surgery, 1 day/week, Wilmer Eye Institute, Johns Hopkins University
07/2010 – present
07/2010 – present
Clinical Program Building/Leadership
10/1/2004 – 2/14/2010 Head of the Clinical Electrophysiology Unit (ISCEV standard for Electroretinography,
Electro-Oculography, Visual Evoked Potentials) of the Dept. of Ophthalmology,
University of Bonn.
10/1/2004 – 2/14/2010 Head of the Low Vision Center, Dept. of Ophthalmology, University of Bonn.
7/31/2006 - 2/14/2010 Coordinator and Supervising Ophthalmologist of the Specialized Clinic Inherited Retinal
and Macular Diseases, Dept. of Ophthalmology, Univ. of Bonn.
10/1/2006 - 2/14/2010 Co- Coordinator and Supervising Ophthalmologist of the Specialized Clinic for
Pseudoxanthoma Elasticum. Dept. of Ophthalmology, University of Bonn.
3/1/2008 – 2/14/2010
„European Vision Institute – Clinical Trials – Sites of Excellence“ (EVI.CT.SE).
07/2010 – present
07/2010 – present
18
Clinical Trials (Current)
•
A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of
Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients with
Macular Edema Secondary to Branch Retinal Vein Occlusion; JHU IRB: NA_00071981; Sponsor:
Regeneron Pharmaceuticals, Inc.; Principal Investigator: Peter A. Campochiaro, MD: Co-Investigator
•
Phase 1b/2a Open-Label, Multiple Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot
Efficacy, Pharmacokinetics and Pharmacodynamic effects of 28-Day Repeat Subcutaneous Doses of
AKB-9778 in Subjects with Diabetic Macular Edema; JHU IRB: NA_00074750; Sponsor: Ora, Inc, Inc.;
Principal Investigator: Peter A. Campochiaro, MD: Co-Investigator
•
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for
Diabetic Macular Edema (Protocol T); JHU IRB: NA_00072168; Sponsor: Diabetic Retinopathy Clinical
Research Network (DRCR)/National Institute of Health (NIH); Principal Investigator: Sharon Solomon,
MD: Co-Investigator
•
A Phase 1, Double Blind, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week
Daily Dosing of ALK-001 in Subjects with Macular Degeneration; JHU IRB: NA_00073266; Sponsor:
Alkeus Pharmaceuticals, Inc.: Principal Investigator
•
A Phase 2/3 Randomized, Double-Bllind, Placebo-Controlled Study to Assess the Efficacy and Safety of
ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP); JHU IRB: NA_00081138;
Sponsor: Isis Pharmaceuticals, Inc.; Principal Investigator: Michael Polydefkis, MD: Co-Investigator
•
A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and
Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious
Uveitis of the Posterior Segment of the Eye; JHU IRB: NA_00066332; Sponsor: Santen Pharmaceutical
Company, Ltd.; Principal Investigator: Peter A. Campochiaro, MD, MSc: Co-Investigator
•
An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and
Vision Outcome in Subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due
to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol
Acyltransferase (LRAT) (Extension of Study RET IRD 01); JHU IRB: NA_00071649; Sponsor: QLT
Phototherapeutics, Inc.: Principal Investigator
•
An Open-Label, Phase 1b Safety/Proof-of-Concept Study to Evaluate the Effects of Oral QLT091001 in
Subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited
Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin: Retinol Acyltransferase
(LRAT); JHU IRB: NA_00065438; Sponsor: QLT Phototherapeutics, Inc.: Principal Investigator
•
Macular Pigment Optical Density in people with retinal degeneration; JHU IRB: NA_00068353; Sponsor:
Foundation Fighting Blindness grant CF-CL-0611-0516-JHU); Ocular Albinism Fund (#80026229),
Clark Charitable Foundation Inc.: Principal Investigator
•
Structure-Function Correlation in Retinal Degeneration; JHU IRB: NA_00044252; Sponsor: Wynn-Gund
Translational Research Acceleration Program Enhanced Research and Clinical Training Award, National
Neurovision Research Institute (NNRI) – Foundation Fighting Blindness (FFB; NNCD-CL-0310.0049JHU-WG), Macular Degeneration Research Award, American Health Assistance Foundation (AHAF;
M2010042): Principal Investigator
•
Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal
Photocoagulation for Proliferative Diabetic Retinopathy - Protocol S. Diabetic Retinopathy Clinical
Research Network (DRCR.net); Sponsor: National Eye Institute (NEI/NIH); Principal Investigator:
Sharon Solomon, MD: Co-Investigator
19
•
Genes in Diabetic Retinopathy Project. Diabetic Retinopathy Clinical Research Network (DRCR.net);
Sponsor: National Eye Institute (NEI/NIH): DRCR Chair for Study Coordination and Co-Investigator
•
National Ophthalmic Genotyping Network, Stage 1—Creation of Repository for Inherited Ophthalmic
Diseases; JHU IRB: NA_00019419; Sponsor: National Eye Institute (NEI/NIH); Principal Investigator:
John Gottsch, MD: Co-Investigator
SYSTEM INNOVATION AND QUALITY IMPROVEMENT
2005 – 2008
Quality Management at the Dept. of Ophthalmology, University of Bonn.
Quality Management Representative for Research.
Certification of the department according to DIN EN ISO 9001 in 2008
http://www.uni-augenklinik.uni-bonn.de/
2008 – 2010
Clinical Trial Center of the Dept. of Ophthalmology, Univ. of Bonn.
Certified by the European agency „European Vision Institute – Clinical Trials – Sites of
Excellence“ (EVI.CT.SE) in 2009
http://www.europeanvisioninstitute.org/CT_SE/index.html
ORGANIZATIONAL ACTIVITIES
Institutional Administrative Appointments
2008 – 2010
„European Vision Institute – Clinical Trials – Sites of Excellence“ (EVI.CT.SE)
2010 – 2011
Member of the Search Committee for the Nanotechnology for Eye Faculty Position at
Johns Hopkins.
2011
Member of the Search Committee for the Retina Division (Wilmer Eye Institute, Johns
Hopkins University) Faculty Position at Wilmer Eye Institute for Including National
Capitol Region.
2012
Member of two subcommittees of the Wilmer’s Board of Governors initiated End
Blindness by the year 2020 Initiative: (1) Wet Age-related Macular Degeneration; (2)
Retinal Degenerations and Dry Age-related Macular Degeneration.
2013
Co-Chair of the Search Committee for the Retina Division (Wilmer Eye Institute, Johns
Hopkins University) Faculty Position for a fellowship-trained, Board Eligible/Board
Certified ophthalmologists specializing in hereditary retinal degenerations.
2013
Co-Chair of the Search Committee for the Retina Division (Wilmer Eye Institute, Johns
Hopkins University) Faculty Position for a fellowship-trained, Board Eligible/Board
Certified ophthalmologist specializing in retina.
Editorial Activities
Editorial Board Appointments
2013 – present Editorial Board, JAMA Ophthalmology
2012 – present Editorial Board, Translational Vision Science & Technology (TVST)
2006 – 2009
Section Editor, Ophthalmologe
20
Journal Peer-Review Activities (Ad-hoc Reviewer):
Acta Ophthalmologica
American Journal of Human Genetics
American Journal of Ophthalmology
Archives of Ophthalmology
Atherosclerosis
BMC Medical Genetics
BMC Ophthalmology
British Journal of Ophthalmology
Clinical Ophthalmology
Computer Methods and Programs in Biomedicine
Documenta Ophthalmologica
European Journal of Medical Genetics
Experimental Eye Research
Expert Reviews in Molecular Medicine
Eye (London)
Genetics in Medicine
Graefe’s Archive for Clinical and Experimental Ophthalmology
Human Genetics
Indian Journal of Ophthalmology
Investigative Ophthalmology and Visual Science
Journal of Molecular Pathology
Klinische Monatsblätter für Augenheilkunde
LANCET
Molecular Vision
Ophthalmic Genetics
Ophthalmic Research
Ophthalmologe
Ophthalmology
PLoS Medicine
Proceedings of the National Academy of Sciences (PNAS)
RETINA
SCIENCE
Value in Health
Grant review activities (Ad-hoc Reviewer):
Agence Nationale de la Recherche (ANR - French National Research Agency), General directorate for healthcare
provision (DGOS - Ministry of social affairs and health), France
Deutsche Forschungsgemeinschaft (DFG – German Research Foundation), Germany
Fonds zur Förderung der wissenschaftlichen Forschung (FWF - Austrian Science Fund), Austria
Foundation Fighting Blindness (FFB)
Medical Research Council (MRC), NIHR Biomedical Research Centre, United Kingdom
Wellcome Trust, United Kingdom
21
Professional Societies
1998 – present Association of Research in Vision and Ophthalmology (ARVO; http://www.arvo.org)
1999 – present Deutsche Opthalmologische Gesellschaft [German Ophthalmological Society] (DOG;
http://www.dog.org/)
1999 – 2010
Berufsverband der Augenärzte Deutschlands (BVA; http://www.augeninfo.de/index.php)
2004 – present International Physicians for the Prevention of Nuclear War (IPPNW; http://www.ippnw.org/)
2005 – 2010
Retinologische Gesellschaft (http://www.retinologie.org/)
2011 – present Macula Society (http://www.maculasociety.org/)
2011 – present Retina Society (http://www.retinasociety.org/)
Conference Organization (selected)
May 2005
Organizer and Chair, Special Interest Group „Phenotyping age-related macular disease (AMD):
Morphology, Imaging and Visual Function” - Joint Meeting of the EVI-GENORET Consortium
and the PHOTAGE Group. Annual Meeting of the Association for Research in Vision and
Ophthalmology (ARVO), Fort Lauderdale, USA.
Feb 2006
Organizer and Chair, Third Annual Meeting of PHOTAGE, Bonn
May 2006
Organizer and Chair, Special Interest Group „Immunological factors in the pathogenesis of agerelated macular degeneration”. Annual Meeting of the Association for Research in Vision and
Ophthalmology (ARVO), Fort Lauderdale, USA.
Oct 2007
Organizer and Chair, Patient Symposium “Age-related Macular Degeneration AMD”. 30. Annual
Meeting of PRO RETINA, Neuss (http://www.pro-retina.de/).
Dec 2007
Session Organizer and Chair, „AMD - The challenge of the 21st Century“. EURPEAN VISION
SUMMIT, Interlaken, Schweiz (http://www.europeanvisioninstitute.org/summit2007.html).
March 2009
Co-Organizer, 1st Annual Meeting of EuroVisionNet. March 19 2009, Bonn
March 2009
Organizer and Chair, The AGEING EYE Conference. March 20-21 2009, Bonn
(http://www.eurovisionnet.eu/news/news-ageingeye_2009.html)
July 2009
Co-Organizer, International PXE Workshop “An update on Pseudoxanthoma Elasticum Perspectives and future directions”, July 3-4 2009, Bonn (http://www.pxe2009.de/)
January 2010
Session Chair: “Retinal Vascular Disease”, Macula 2010, January 23 2010, Johns Hopkins
University School of Medicine, Baltimore.
Dec 2010
Session Chair: “Retina”. 23rd Annual Current Concepts in Ophthalmology, Johns Hopkins
University, Baltimore.
March 2011
Session Organizer: Imaging I/Imaging II, The 2nd World Congress on Controversies in
Ophthalmology (COPHy), Barcelona, Spain.
June 2011
Session Chair: Usher Syndrome, Foundation Fighting Blindness’ national conference, VISIONS,
Baltimore.
June 2011
Session Chair: New Horizons in Retina, New Horizons in Retina: Celebrating New
Breakthroughs in Prevention and Treatments with a World-Renowned Faculty, Victor, Idaho.
June 2012
Session Chair: “Neovascular AMD”. Age-Related Macular Degeneration in 2012: The Paradigm
Continues to Evolve. Johns Hopkins University, Baltimore.
March 2013
Session Chair: “Retina I (Imaging and Genetics)”; “The Future of Retina May Not Be AntiVEGF Monotherapy - A Perspective from Industry”, 3rd World Congress on Controversies in
Ophthalmology (COPHy), Budapest, Hungary.
22
Consultantships
2005
2006 – 2008
2008
2011 – 2012
from 2011
from 2012
from 2012
from 2012
Easton Associates, L.L.C., New York, USA
GENACTIS GmbH, Cologne, Germany
Optherion, Inc., New Haven, USA
QLT Inc., Vancouver, BC, Canada
Member of the Scientific and Advisory Committee of the Institut de la Vision, Paris
Sanofi- Fovea, Paris, France: Gene Therapy in Stargardt Disease and Usher Syndrome
StemCells Inc., Newark, California: Data Monitoring Committee for “Phase I/II study of the
safety and preliminary efficacy of HuCNS-SC subretinal transplantation in subjects with
geographic atrophy of age-related macular degeneration”
Ophthalmic Devices Panel of the Medical Devices Advisory Committee, Food and Drug
Administration (FDA), Silver Spring, Maryland, USA
RECOGNITION
Awards, Honors
2001
International Society for Clinical Electrophysiology of Vision (ISCEV) Travel Award
Awarded Abstract: Scholl HPN et al. Slow and fast rod ERG pathways in patients with X-linked
complete stationary night blindness carrying mutations in the NYX gene. ($600)
2002
Presentation Award of the fortüne/AKF-Colloquium Oct 10th 2002
Awarded Presentation: Scholl HPN & Kremers J, L- and M-cone driven ERGs in cone and conerod dystrophies. (EUR 500)
2002
Elfriede-Aulhorn Award of the Neuro-Ophthalmological Society
Awarded Paper: Scholl HPN et al. L- and M-cone driven electroretinograms in Stargardt's
macular dystrophy-Fundus flavimaculatus. Investigative Ophthalmology & Visual Science.
2001;42:1380-1389. (EUR 5,000)
2003
PHARAMCIA 2003 ARVO Travel Award
Awarded Abstract: Scholl HPN et al. Photopic and scotopic fine matrix maping of retinal areas
of increased fundus autofluorescence in patients with age-related maculopathy (ARM) and
macular degeneration (AMD). Investigative Ophthalmology & Visual Science. 2003
(Suppl);43:5030. (BP 350)
2003
Macula Degeneration Award 2003 of Pro Retina Germany
Awarded Papers: (1) Scholl HPN et al. Alterations of slow and fast rod ERG signals in patients
with molecularly confirmed Stargardt disease type 1 (STGD1). Investigative Ophthalmology &
Visual Science. 2002;43:1248-1256; (2) Scholl HPN et al. Mapping of retinal function in Best
macular dystrophy using multifocal electroretinography. Vision Research. 2002;42:1053-1061.
(EUR 3,500)
2006
Research Award of the German Ophthalmological Society
Awarded Research Work and Proposal: Fleckenstein M, Scholl HPN & Holz FG, GenotypePhenotype-Correlation in Patients with Geographic Atrophy due to Age-related Macular
Degeneration. (EUR 25,000)
2008
KROENER Research Award
Awarded Paper: Scholl HPN, Charbel Issa P et al. Systemic complement activation in age-related
macular degeneration. PLoS ONE. 2008;3(7): e2593. (EUR 10,000)
2008
European Vision Award 2008
Awarded by the European Vision Institute
(http://www.europeanvisioninstitute.org/award_2008-hendrik_scholl.html)
2010
Wynn-Gund Translational Research Acceleration Program Enhanced Research and Clinical
Training Award
23
Awarded by the National Neurovision Research Institute – Foundation Fighting Blindness
($510,000)
2010
Macular Degeneration Research Award
Awarded by the American Health Assistance Foundation (AHAF)
(http://www.ahaf.org/research/grants/migrated/structure-function.html)
($100,000)
2011
The Dr. Frieda Derdeyn Bambas Professorship of Ophthalmology
Wilmer Eye Institute, Johns Hopkins University
2013
Visionary Award
Awarded by the Foundation Fighting Blindness (FFB)
2014
ARVO Foundation/Pfizer Ophthalmics Carl Camras Translational Research Award
Awarded by the Association for Research in Vision and Ophthalmology (ARVO)
(http://arvo.org/Awards_and_Grants/Awards/2014_Achievement_Award_recipients/)
($10,000)
Invited Lectures (2006-2013)
5/16/2006
“Research in age-related macular degeneration”. AMD Alliance, AMD Global Meeting, Brussels.
5/18-21/2006
(1) “Fundus autofluorescence in age-related macular degeneration”; (2) “Phenotyping AMD in
the EVI-GENORET consortium”. 6th EURETINA Congress, Lisboa.
6/10/2006
“Correlation of CFH Y402H and LOC387715 A69S allele distribution and progression of
geographic atrophy in patients with age-related macular degeneration”. 19th Annual Congress of
the German Retina Society and Nordic Vitreoretinal Society, Kiel.
9/1/2006
“Correlation of CFH Y402H and LOC387715 A69S allele distribution and progression of
geographic atrophy in patients with age-related macular degeneration”. DFG SPP 1088 Workshop
“The Challenge of understanding Age-related Macular Degeneration: Current approaches and
Future Research Perspectives”, Bonn.
9/9/2006
“Genetics of retinal disorders”. X. Congress of the International Society of Ocular Toxicology,
Königswinter.
9/21-24/2006
(1) “Genetic factors of AMD including complement factor H [Genetische Faktoren der AMD
inklusive Komplement Faktor H]”; (2) “Establishing Ophthalmology in the research framework
programs of the European Union”.104. Congress of the German Ophthalmological Society,
Berlin.
11/2/2006
“New pharmacolog treatments for age-related macular degeneration [Neue medikamentöse
Therapien bei der altersabhängigen Makuladegeneration]”. Münchner Ophthalmologisches
Curriculum, Munich.
4/27/2007
“Breaking News: Genetic factors in AMD [Genetische Faktoren der AMD]”. Makula-Update
2007, Bonn.
6/12/2007
(1) “Epidemiologic aspects and genetic factors in AMD”; (2) “Functional imaging in age-related
macular degeneration”. Joint Congress of SOE /AAO 2007, Vienna.
7/2/2007
“Age-related macular degeneration”. “HEARING AND SEEING: Joined European efforts for
fighting sensory disabilities”, Joint Meeting of the EURHEAR and EVI-GENORET consortia,
Paris.
9/6/2007
“Complement gene variants and systemic complement protein alterations in AMD”. 4th
International Symposium of the German Ophthalmological Society (DOG): Age-Related Macular
Degeneration – Pathogenesis and Treatment, Baden-Baden.
24
9/22/2007
“Genetics of AMD – new perspectives [Genetik der AMD – neue Perspektiven]”. 105. Congress
of the German Ophthalmological Society, Berlin.
10/5/2007
“Age-related macular degeneration: a genetic, immunologic and systenic disease [Die
altersabhängige Makuladegeneration: eine genetische, immunologische und systemische
Erkrankung]”. 232. Freiburger Augenärzteabend, University Hospital Freiburg.
10/21/2007
(1) “Microperimetry in Macular Telangiectasia”; (2) “Macular Telangiectasia and
Autofluorescence”. MacTel Research Project - Bi-annual Meeting, Sydney.
11/24/2007
“Imaging in Medical Retina”. OPHTHALMOLOGIA BELGICA, Brussels.
11/27/2007
“Genetics of age-related macular degeneration [Die Genetik der altersabhängigen
Makuladegeneration]”. Biologisch-Naturwissen¬schaftl¬iche Sektion, Fortbildungsakademie der
Ärztekammer Hamburg, „Komplexe multigene Erkrankungen – Licht am Ende des Tunnels“,
Hamburg.
12/4/2007
(1) “The socioeconomic impact of age-related macular degeneration”; (2) “Functional imaging in
age-related macular degeneration”. EUROPEAN VISION SUMMIT, Interlaken, Switzerland.
2/8/2008
“Genetics of age-related macular degeneration [Genetik der altersabhängigen
Makuladegeneration]”. 170. Versammlung des Vereins Rheinisch-Westfälischer Augenärzte,
Wuppertal.
3.7.2008
“Macular Dystrophies [Makuladystrophien]”. Augenärztliche Akademie 2008, Düsseldorf.
3/13/2008
“Genetic advances and therapeutic consequences in AMD”. “Potential therapeutic concepts in
age-related macular degeneration” Meeting, Royal Society of Medicine, London.
3/14/2008
(1) “Retinal imaging and the consequences of findings”; (2) “Complement genes and systemic
complement activation in AMD”. The Amsler Club Meeting, London.
3/28/2008
“Systemic complement activation in AMD”. Pro Retina-Research Colloquium 2008, Potsdam.
4/11/2008
“AMD update: Phenotype-Genotype Correlation and Protein Marker [AMD Update: PhänotypGenotyp-Korrelation und Proteinmarker]”. Makula-Update 2008, Leipzig.
5/17/2008
“Complement inhibition – AMD treatment in the future?” 11th Vitreoretinal Symposium,
Marburg.
7/11/2008
“Current Therapeutic Options for Age-related Macular Degeneration [Aktuelle Therapie der
altersabhängigen Makuladegeneration]”. 40th Course on Retinal Detachment (Wacker-Kurs),
Dept. of Ophthalmology, LMU Munich.
9/18-21/2008
(1) “Genetic biomarkers for retinal diseases”; (2) “Therapeutic consequences of the genetic
variants in age-related macular degeneration [Therapeutische Konsequenzen der genetischen
Faktoren bei der altersabhängigen Makuladegeneration]”; (3) “European networks in ophthalmic
research [Europäische Netzwerke in der ophthalmologischen Forschung]”. 106. Congress of the
German Ophthalmological Society, Berlin.
10/3/2008
“Genotyping and Phenotyping – Therapeutic consequences for monogenic retinal dystrophies and
age-related macular degeneration”. Lecture of the European Vision Awardee at the European
Association for Vision and Eye Research (EVER) meeting, Portoroz, Slovenia.
11/1/2008
“Reading Performance in in Macular Telangiectasia Type 2”. MacTel Research Project - Biannual Meeting, London.
11/19/2008
“Macular Degeneration [Makuladegeneration]”. UNIVADIS online-WebCast
11/22/2008
“Future Therapeutic Options for Age-related Macular Degeneration [Zukünftige
Therapieoptionen bei der altersabhängigen Makuladegeneration]”. Patient Symposium of Pro
Retina Deutschland and LMU, Munich.
3/13/2009
“Macular Dystrophies [Makuladystrophien]”. Augenärztliche Akademie 2009, Düsseldorf.
3/21/2009
“Age-related Eye Diseases: From Genes to Therapy”. The AGEING EYE Conference, Bonn.
5/14/2009
“Identifying Progression of Dry AMD”. 8th EURETINA Congress, Nice.
25
6/26/2009
“Causes of age-related macular degeneration: Role of genetics and inflammation [AMDUrsachen: Welche Rolle spielen Genetik und Entzündung?]” 22nd Annual Congress of the
German Retina Society, Berlin.
7/4/2009
“High-Resolution SD-OCT of Bruch’s Membrane in PXE”. International PXE Workshop, Bonn.
7/17/2009
“Current Therapeutic Options for Age-related Macular Degeneration [Aktuelle Therapie der
altersabhängigen Makuladegeneration]”. 41st Course on Retinal Detachment (Wacker-Kurs),
Dept. of Ophthalmology, LMU Munich.
9/24-27/2009
(1) “AMD: A systemic disease with ophthalmic manifestations? [AMD: Eine systemische
Erkrankung mit Manifestation am Auge?]”; (2) “Causes and prevention of AMD – current state
of the art [Ursachen und Prävention der AMD – Stand der Dinge]”. 107. Congress of the German
Ophthalmological Society, Leipzig.
12/3-5/2009
(1) “What Should We Do About Hereditary Retinal Conditions?”; (2) “Management of nonneovascular "dry” AMD”. Current Concepts in Ophthalmology, Johns Hopkins University School
of Medicine, Baltimore.
4/9/2010
“Structure-Function Correlation of the Human Central Retina”. Pro Retina-Research Colloquium
2010, Potsdam.
6/6/2010
“Genetics and prevention of AMD”. World Ophthalmology Congress, Berlin.
9/23/2010
US Congress Briefing
hosted by the Alliance for Eye and Vision Research’s (AEVR) Decade of Vision 2010-2020
Initiative, co-hosted by the AMD Alliance International (AMDAI), the Association for Research
in Vision and Ophthalmology (ARVO), and the European Vision Institute (EVI)
“Age-related Macular Degeneration: From Gene to Therapy”
(http://www.eyeresearch.org/naevr_action/AMD2010.html)
11/15-17/2010 WORLD HEALTH ORGANIZATION, Prevention of Blindness & Deafness
WHO Consultation on the public health approaches to the management of age-related macular
degeneration, Rome, Italy.
“AMD management guidelines currently in use”
12/3/2010
“Retinal Degenerations: State-of-the-art Evaluation and Emerging Therapy”. 23rd Annual Current
Concepts in Ophthalmology, Johns Hopkins University, Baltimore
12/11/2010
“Vitrectomy for Proliferative Diabetic Retinopathy”, What’s New in Diabetic Retinopathy and
Venous Occlusive Disease, Course, Johns Hopkins University School of Medicine, Baltimore.
3/5/2011
“Structure-Function Correlation of the Central Human Retina”.
The 2nd World Congress on Controversies in Ophthalmology (COPHy).
Catalonia Palace of Congresses, Barcelona, Spain.
6/30-7/2/2011 “Managing Retinal Degenerations in the Next Decade” and “Genetics and Prevention of AMD”,
New Horizons in Retina: Celebrating New Breakthroughs in Preventions and Treatments with a
World-Renowned Faculty, 41st Anniversary of the Wilmer Eye Institute Retina Division, Teton
Springs Lodge, Victor, Idaho
12/2/2011
“Update on Clinical Trials for Retinal Degenerations”. 24th Annual Current Concepts in
Ophthalmology, Johns Hopkins University, Baltimore
3/23/2012
“Autofluorescence: Pros and Cons”. 3rd World Congress on Controversies in Ophthalmology
(COPHy), Istanbul, Turkey.
3/29/2012
US Congress Hearing
Public Witness hearing of the House Labor, Health and Human Services, and Education (LHHS)
Appropriations Subcommittee; Representing the National Alliance for Eye and Vision Research’s
(NAEVR)
(http://www.eyeresearch.org/naevr_action/Scholl_Testifys_032912.html)
26
6/9/2012
“Update on Autofluorescence and OCT in AMD”. Age-Related Macular Degeneration in 2012:
The Paradigm Continues to Evolve. Johns Hopkins University, Baltimore.
9/22/2012
(1) “A state-of-the-art in SD-OCT: Retinal morphology relevant for retinal disease”; (2) “
Genetics of the visual cycle – consequences for supplementation and therapy”. 110. Congress of
the German Ophthalmological Society, Berlin.
10/6/2012
“Increased Vision with QLT091001 in Blindness due to Mutations in Retinal Pigment
Epithelium-specific Protein 65kDa (RPE65) or Lecithin Retinol Acyltransferace (LRAT)”. 45th
Annual Meeting of the Retina Society, Washington D.C.
11/9/2012
“Increased Vision with QLT091001 in Blindness due to Mutations in Retinal Pigment
Epithelium-specific Protein 65kDa (RPE65) or Lecithin Retinol Acyltransferase (LRAT). Phase
1b Study in Subjects with Retinitis Pigmentosa”. American Academy of Ophthalmology, Retina
Subspecialty Day, Chicago
12/1/2012
“Genetics of the Visual Cycle – Consequences for Supplementation and Therapy”. ART 2012
Meeting: Past – Present Perspectives in Ophthalmology, Vienna
12/7/2012
“Update on Clinical Trials for Retinal Degenerations”. 25th Annual Current Concepts in
Ophthalmology, Johns Hopkins University, Baltimore
1/11/2013
“Does the genotype allow to draw conclusions on the AMD phenotype including exudative versus
atrophic AMD ?” Macula of Paris 2013, Paris
1/19/2013
“Autofluorescence in Macular Degeneration – Just the Facts”. MACULA 2013, Johns Hopkins
University, Baltimore
2/26/2013
“Radial Streaking in the Fundus”. International Retinal Imaging Symposium (IRIS), Jules Stein
Eye Institute, Los Angeles
3/13/2012
US Congress Hearing
Public Witness hearing of the House Labor, Health and Human Services, and Education (LHHS)
Appropriations Subcommittee; Representing the National Alliance for Eye and Vision Research’s
(NAEVR)
(http://www.eyeresearch.org/naevr_action/Scholl_Testify_FY2014.html)
4/5/2013
“Role of ICG angiography” and “Role of genetics in AMD progression”. 4th World Congress on
Controversies in Ophthalmology (COPHy), Budapest, Hungary.
27

CURRICULUM VITAE Hendrik Peter Nicolas Scholl

Transcription

Similar documents

Psychosomatik chronisch-entzündlicher Darmerkrankungen

2/2012 - Deutsche Gesellschaft für Endokrinologie